Breaking News
Get 50% Off 0
🌎 30+ NEW AI-picked stock strategies for exciting international markets
Unlock Global AI Picks

Zacks Investment Research Zacks Investment Research

Zacks Investment Research's Opinion & Analysis.
Featured here: a complete archive of all posts and research produced by Zacks Investment Research, including current material.
DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 Revenues By Zacks Investment Research - Jan 10, 2022

DexCom Inc. DXCM recently released preliminary fourth-quarter and full-year 2021 revenue results.Per the preliminary announcement, DexCom — the leader in continuous glucose monitoring (CGM)...

Nokia (NOK) Likely to Exceed 2021 View on One-Time Benefits By Zacks Investment Research - Jan 10, 2022

Nokia (NYSE:NOK) Corporation NOK recently offered investors a preview of its upcoming quarterly and full-year results and provided bullish projections for 2022 on the back of healthy growth drivers....

AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS By Zacks Investment Research - Jan 10, 2022

AbbVie ABBV has submitted regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of its JAK inhibitor drug, Rinvoq (upadacitinib) for the treatment of adults with...

Dynex Capital (DX) Gains As Market Dips: What You Should Know By Zacks Investment Research - Jan 10, 2022

Dynex Capital (NYSE:DX) closed at $16.92 in the latest trading session, marking a +0.06% move from the prior day. This change outpaced the S&P 500's 0.14% loss on the day. Meanwhile, the Dow lost...

Limoneira (LMNR) Reports Q4 Loss, Tops Revenue Estimates By Zacks Investment Research - Jan 10, 2022

Limoneira (LMNR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.42 per share a year ago. These figures are...

5 Great Value Options to Buy Right Now By Zacks Investment Research - Jan 10, 2022

Sometimes even good news can be bad news. Like an unemployment situation that continues to improve. Or a manufacturing economy that continues to expand -- with a backdrop where the Fed must raise...

5 Best Inverse/Leveraged ETF Areas of Last Week By Zacks Investment Research - Jan 10, 2022

The first week of 2022 turned somber for Wall Street as the S&P 500 lost 1.9%, the Dow Jones skidded 0.3%, the Nasdaq Composite lost 4.5% and the Russell 2000 was off 2.9%. Notably, the Nasdaq...

4 Sector ETFs to Play Despite Soft December Jobs Data By Zacks Investment Research - Jan 10, 2022

The U.S. economy added 199,000 jobs in December 2021, well below market forecasts of 400,000. Non-farm employment has increased by 18.8 million since April 2020 but is still down by 2.3% from its...

Apple (AAPL) to Reopen iPhone Manufacturing Factory in India By Zacks Investment Research - Jan 09, 2022

Apple AAPL recently addressed one of its supply chain constraints stemming from Labor Law Violations in India. In December, Apple put its key manufacturing partner Foxconn’s factory in India on...

Regeneron (REGN) Collaborates With Ultragenyx for Evkeeza By Zacks Investment Research - Jan 09, 2022

Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. REGN recently announced a license and collaboration agreement with Ultragenyx Pharmaceutical (NASDAQ:RARE) Inc. RARE. Per the deal, RARE gets the rights...

Are Options Traders Betting on a Big Move in iQIYI (IQ) Stock? By Zacks Investment Research - Jan 09, 2022

Investors in iQIYI, Inc. IQ need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 17, 2022 $5.00 Call had some of the highest implied volatility...

Continue with Apple
Continue with Google
or
Sign up with Email